… the expression of surface antigen CD56 and the prognosis of de novo none-M3 AML patients
… that high levels of CD56 expression are a factor for poor prognosis in de novo non-M3 AML …

… in AML patients. Our results showed the expression rate of CD56 in AML patients was 17.3%.
… In conclusion, CD200 + and CD56 + expression in AML at diagnosis are poor prognostic …

… on prognosis: CD7, CD56, CD15, CD2, CD3, CD90 low , CD123 high , CD117 high , and
three others were associated with good prognosis: … expression of CD56 as a poor prognostic …

… 2017; 176:498) reported that CD56 positive is associated with poor prognosis of patients
with intermediate-risk acute myeloid leukemia (IR-AML). However, our data were inconsistent …

… patients of acute myeloid leukaemia could be indicative of poor prognosis as it was also
associated … survival with respect to CD56 negative patients which correlated with our results. …

… Of all phenotypes, CD56 was related most clearly to an unfavorable prognosis. The CR rate,
… overall survival of CD56 + APL were not significantly different compared with CD56 − APL. …

… such as decreased overall survival and low rates of complete … that within CD56-positive
leukemias, poor prognosis is … than 80% of patients with a CD56 expression greater than 1.55 log …

… The results of this study indicated that the expression intensity of CD117, CD13, CD56, CD64,
and MPO antigens in APL are significantly different from HLA-DR-negative AML. Besides, …

… low-risk group (χ 2 = 14.779, p < 0.001). This study showed that the decreased expression of
CD86 in CD3 + CD56 … SAE in septic patients usually indicates a poor prognosis and is also …

… , or heavy and light chains of patients. Skerget et al … CD56 expression and age, gender or
high-risk genetic factors. Although absence of CD56 is considered a criterion for poor prognosis…